Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort. Issue 4 (18th December 2017)

• Record Type: Journal Article
• Authors: Tadbiri, S.; Peyrin‐Biroulet, L.; Serrero, M.; Filippi, J.; Pariente, B.; Roblin, X.; Buisson, A.; Stefanescu, C.; Trang‐Poisson, C.; Altwegg, R.; Marteau, P.; Vaysse, T.; Bourrier, A.; Nancey, S.; Laharie, D.; Allez, M.; Savoye, G.; Gilletta, C.; Gagniere, C.; Vuitton, L.; Viennot, S.; Aubourg, A.; Pelletier, A.‐L.; Bouguen, G.; Abitbol, V.; Fumery, M.; Claudepierre, P.; Bouhnik, Y.; Amiot, A.
• Other Names: Amiot Aurelien investigator.; Gagniere Charlotte investigator.; Serrero Melanie investigator.; Grimaud Jean‐Charles investigator.; Peyrin‐Biroulet Laurent investigator.; Zallot Camille investigator.; Bigard Marc‐Andre investigator.; Filippi Jerome investigator.; Hebuterne Xavier investigator.; Pariente Benjamin investigator.; Nachury Maria investigator.; Desreumaux Pierre investigator.; Roblin Xavier investigator.; Del Tedesco Emilie investigator.; Buisson Anthony investigator.; Bommelaer Gilles investigator.; Stefanescu Carmen investigator.; Bouhnik Yoram investigator.; Boureille Arnaud investigator.; Trang‐Poisson Caroline investigator.; Altwegg Romain investigator.; Marteau Philippe investigator.; Dray Xavier investigator.; Carbonnel Franck investigator.; Vaysse Thibaud investigator.; Seksik Philippe investigator.; Beaugerie Laurent investigator.; Cosnes Jacques investigator.; Sokol Harry investigator.; Landman Cecilia investigator.; Bourrier Anne investigator.; Nancey Stephane investigator.; Boschetti Gilles investigator.; Laharie David investigator.; Poullenot Florian investigator.; Allez Matthieu investigator.; Gornet Jean‐Marc investigator.; Baudry Clautilde investigator.; Savoye Guillaume investigator.; Moreau Jacques investigator.; Vuitton Lucine investigator.; Koch Stephane investigator.; Viennot Stephanie investigator.; Aubourg Alexandre investigator.; Picon Laurence investigator.; Pelletier Anne‐Laure investigator.; Sickersen Gaelle investigator.; Bouguen Guillaume investigator.; Abitbol Vered investigator.; Chaussade Stanislas investigator.; Fumery Mathurin investigator.; Nahon Stephane investigator.; Winkfield Betsy investigator.; Brixi‐benmansour Hedia investigator.; Gincul Rodica investigator.; Barberis Jean‐Christophe investigator.; Bonaz Bruno investigator.; Michiels Christophe investigator.; Zerbib Franck investigator.; Bourrier de Beauregard Marie investigator.; Locher Christophe investigator.; Davin‐Couve Sophie investigator.; Poirette Armelle investigator.; Guillem Laurence investigator.; Stetiu‐Mocanu Monica investigator.; Philippe Beau investigator.; Beorchia Sylvain investigator.; Al Qaddi Jawad investigator.;
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 47:Issue 4(2018)
• Page Start: 485
• Page End: 493
• Publication Date: 2017-12-18
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.14419
• Languages: English
• ISSNs: 0269-2813

Abstract

Summary: Background: The effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut‐specificity. Aim: To assess effectiveness of vedolizumab for EIM in patients with inflammatory bowel disease (IBD) in a large real‐life experience cohort. Methods: Between June and December 2014, 173 patients with Crohn's disease and 121 with ulcerative colitis were treated with vedolizumab. Patients were followed until week 54. EIM activity was assessed at weeks 0, 6, 14, 22, 30 and 54 by using a 3‐step scale: complete remission, partial response and no response. Results: At baseline, 49 (16.7%) patients had EIMs of which 47 had inflammatory arthralgia/arthritis, four had cutaneous lesions and two had both rheumatologic and skin EIM. At week 54, 21 (44.7%) patients had complete remission for inflammatory arthralgia/arthritis and three (75%) for cutaneous EIM. In multivariate analysis, complete remission of inflammatory arthralgia/arthritis was associated with clinical remission of IBD (OR = 1.89, IC95% [1.05‐3.41], P = .03) and recent onset of inflammatory arthralgia/arthritis (OR = 1.99, IC95% [1.12‐3.52], P = .02). During the follow‐up period, 34 (13.8%) patients without any EIM at baseline, developed incident cases of inflammatory arthralgia/arthritis consisting mostly of peripheral arthralgia without evidence of arthritis and 14 (4.8%) incident cases of paradoxical skin manifestation. Conclusion: Vedolizumab therapy is commonly associated with improvement in EIM. This was associated with quiescent IBD and recent EIM. However, paradoxical skin manifestation and inflammatory arthralgia/arthritis may occur upon vedolizumab therapy. Abstract : Linked Content This article is linked to Barclay and Stamp paper. To view this article visithttps://doi.org/10.1111/apt.14465 .